vs
Side-by-side financial comparison of Karyopharm Therapeutics Inc. (KPTI) and LINKBANCORP, Inc. (LNKB). Click either name above to swap in a different company.
LINKBANCORP, Inc. is the larger business by last-quarter revenue ($46.0M vs $34.1M, roughly 1.4× Karyopharm Therapeutics Inc.). LINKBANCORP, Inc. runs the higher net margin — 6.4% vs -299.9%, a 306.3% gap on every dollar of revenue. On growth, Karyopharm Therapeutics Inc. posted the faster year-over-year revenue change (11.6% vs 7.3%). Over the past eight quarters, LINKBANCORP, Inc.'s revenue compounded faster (6.6% CAGR vs 1.4%).
LINKBANCORP, Inc. is a US-based bank holding company that offers comprehensive retail and commercial banking services to individual consumers, small businesses, and mid-sized enterprises. Its core offerings include deposit accounts, lending products, wealth management solutions, and digital banking services, primarily serving customers across regional markets in Pennsylvania.
KPTI vs LNKB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.1M | $46.0M |
| Net Profit | $-102.2M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | -52.4% | 8.5% |
| Net Margin | -299.9% | 6.4% |
| Revenue YoY | 11.6% | 7.3% |
| Net Profit YoY | -232.0% | -61.2% |
| EPS (diluted) | $-7.02 | $0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.1M | $46.0M | ||
| Q3 25 | $44.0M | $44.8M | ||
| Q2 25 | $37.9M | $42.3M | ||
| Q1 25 | $30.0M | $53.4M | ||
| Q4 24 | $30.5M | $42.9M | ||
| Q3 24 | $38.8M | $42.9M | ||
| Q2 24 | $42.8M | $41.3M | ||
| Q1 24 | $33.1M | $40.5M |
| Q4 25 | $-102.2M | $2.9M | ||
| Q3 25 | $-33.1M | $7.8M | ||
| Q2 25 | $-37.3M | $7.4M | ||
| Q1 25 | $-23.5M | $15.3M | ||
| Q4 24 | $-30.8M | $7.6M | ||
| Q3 24 | $-32.1M | $7.1M | ||
| Q2 24 | $23.8M | $5.8M | ||
| Q1 24 | $-37.4M | $5.7M |
| Q4 25 | -52.4% | 8.5% | ||
| Q3 25 | -34.6% | 22.3% | ||
| Q2 25 | -64.3% | 22.4% | ||
| Q1 25 | -110.8% | 36.0% | ||
| Q4 24 | -102.4% | 22.6% | ||
| Q3 24 | -67.8% | 21.3% | ||
| Q2 24 | -65.7% | 18.0% | ||
| Q1 24 | -101.9% | 18.1% |
| Q4 25 | -299.9% | 6.4% | ||
| Q3 25 | -75.2% | 17.5% | ||
| Q2 25 | -98.2% | 17.5% | ||
| Q1 25 | -78.2% | 28.7% | ||
| Q4 24 | -100.8% | 17.7% | ||
| Q3 24 | -82.7% | 16.5% | ||
| Q2 24 | 55.6% | 14.1% | ||
| Q1 24 | -112.8% | 14.1% |
| Q4 25 | $-7.02 | $0.08 | ||
| Q3 25 | $-3.82 | $0.21 | ||
| Q2 25 | $-4.32 | $0.20 | ||
| Q1 25 | $-2.77 | $0.41 | ||
| Q4 24 | $-2.33 | $0.21 | ||
| Q3 24 | $-3.85 | $0.19 | ||
| Q2 24 | $-2.97 | $0.16 | ||
| Q1 24 | $-4.85 | $0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $60.5M | $52.3M |
| Total DebtLower is stronger | — | $177.3M |
| Stockholders' EquityBook value | $-292.9M | $306.4M |
| Total Assets | $108.4M | $3.1B |
| Debt / EquityLower = less leverage | — | 0.58× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.5M | $52.3M | ||
| Q3 25 | $37.7M | $194.2M | ||
| Q2 25 | $38.7M | $155.1M | ||
| Q1 25 | $38.8M | $220.2M | ||
| Q4 24 | $62.5M | $166.1M | ||
| Q3 24 | $72.8M | $191.2M | ||
| Q2 24 | $84.8M | $181.7M | ||
| Q1 24 | $30.6M | $172.3M |
| Q4 25 | — | $177.3M | ||
| Q3 25 | — | $102.3M | ||
| Q2 25 | — | $102.3M | ||
| Q1 25 | — | $102.7M | ||
| Q4 24 | — | $112.5M | ||
| Q3 24 | — | $102.4M | ||
| Q2 24 | — | $102.3M | ||
| Q1 24 | — | $102.2M |
| Q4 25 | $-292.9M | $306.4M | ||
| Q3 25 | $-269.3M | $305.5M | ||
| Q2 25 | $-238.9M | $298.0M | ||
| Q1 25 | $-205.9M | $294.1M | ||
| Q4 24 | $-186.0M | $280.2M | ||
| Q3 24 | $-159.6M | $277.4M | ||
| Q2 24 | $-132.1M | $271.4M | ||
| Q1 24 | $-169.0M | $268.2M |
| Q4 25 | $108.4M | $3.1B | ||
| Q3 25 | $96.2M | $3.1B | ||
| Q2 25 | $104.9M | $2.9B | ||
| Q1 25 | $127.7M | $2.9B | ||
| Q4 24 | $164.4M | $2.9B | ||
| Q3 24 | $189.5M | $2.9B | ||
| Q2 24 | $214.0M | $2.9B | ||
| Q1 24 | $204.5M | $2.8B |
| Q4 25 | — | 0.58× | ||
| Q3 25 | — | 0.33× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.35× | ||
| Q4 24 | — | 0.40× | ||
| Q3 24 | — | 0.37× | ||
| Q2 24 | — | 0.38× | ||
| Q1 24 | — | 0.38× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.8M | $25.3M |
| Free Cash FlowOCF − Capex | — | $23.8M |
| FCF MarginFCF / Revenue | — | 51.7% |
| Capex IntensityCapex / Revenue | 0.0% | 3.2% |
| Cash ConversionOCF / Net Profit | — | 8.59× |
| TTM Free Cash FlowTrailing 4 quarters | — | $55.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.8M | $25.3M | ||
| Q3 25 | $-5.9M | $23.6M | ||
| Q2 25 | $-18.7M | $6.3M | ||
| Q1 25 | $-39.0M | $2.6M | ||
| Q4 24 | $-25.8M | $25.4M | ||
| Q3 24 | $-19.5M | $14.0M | ||
| Q2 24 | $-38.5M | $6.4M | ||
| Q1 24 | $-43.7M | $-771.0K |
| Q4 25 | — | $23.8M | ||
| Q3 25 | — | $23.2M | ||
| Q2 25 | — | $6.1M | ||
| Q1 25 | — | $2.2M | ||
| Q4 24 | $-25.9M | $22.6M | ||
| Q3 24 | — | $13.1M | ||
| Q2 24 | — | $6.3M | ||
| Q1 24 | $-43.9M | $-1.2M |
| Q4 25 | — | 51.7% | ||
| Q3 25 | — | 51.8% | ||
| Q2 25 | — | 14.5% | ||
| Q1 25 | — | 4.2% | ||
| Q4 24 | -84.7% | 52.6% | ||
| Q3 24 | — | 30.5% | ||
| Q2 24 | — | 15.3% | ||
| Q1 24 | -132.6% | -3.0% |
| Q4 25 | 0.0% | 3.2% | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | 0.0% | 0.4% | ||
| Q1 25 | 0.0% | 0.7% | ||
| Q4 24 | 0.2% | 6.7% | ||
| Q3 24 | 0.0% | 2.1% | ||
| Q2 24 | 0.0% | 0.1% | ||
| Q1 24 | 0.6% | 1.1% |
| Q4 25 | — | 8.59× | ||
| Q3 25 | — | 3.01× | ||
| Q2 25 | — | 0.85× | ||
| Q1 25 | — | 0.17× | ||
| Q4 24 | — | 3.35× | ||
| Q3 24 | — | 1.97× | ||
| Q2 24 | -1.62× | 1.10× | ||
| Q1 24 | — | -0.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
LNKB
Segment breakdown not available.
